Shokoufeh Bonakdaran1, Farzaneh Fakhraee1, Maryam Saberi Karimian2, Seyed Reza Mirhafez3, Haleh Rokni4, Mohsen Mohebati4, Mohsen Mazidi4, Mina Mousavi5, Gordon A Ferns6, Majid Ghayour-Mobarhan7. 1. Endocrine Research Center, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 2. Student Research Committee, Department of Modern Sciences and Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 3. Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran; Department of Modern Sciences and Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 4. Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 5. Department of Modern Sciences and Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 6. Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK. 7. Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Biochemistry of Nutrition Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: ghayourm@mums.ac.ir.
Abstract
PURPOSE: There is now good evidence that 25-hydroxyvitamin D (25OHD) status may have an important impact on the development and progression of cardiovascular disease. Because of the potential involvement of vitamin D deficiency in blood pressure control and immune responses, we aimed to investigate whether there was a relationship between 25OHD status and the prevalence of metabolic syndrome in an Iranian population. MATERIAL/ METHODS: The study was carried out on a sample of 846 subjects [357(42.19%) males and 489(57.80%) females], derived from MASHAD STUDY. Serum 25OHD levels were measured using a competitive electroluminescence protein binding assay. Anthropometric indices were measured using standard protocols. RESULTS: Serum 25OHD was 12.7 (6.8-18.4) ng/ml in the metabolic syndrome (MetS) group and 14.1 (8.8-19.0) ng/ml in the group without metabolic syndrome (P=0.43). The frequency of vitamin D deficiency was 80.7% and 79.0% in subjects with or without metabolic syndrome in Iranian population. CONCLUSIONS: We found no significant difference in serum 25OHD concentrations between individuals with or without MetS and no significant linear relationship between serum 25OHD and several CVD risk factors.
PURPOSE: There is now good evidence that 25-hydroxyvitamin D (25OHD) status may have an important impact on the development and progression of cardiovascular disease. Because of the potential involvement of vitamin D deficiency in blood pressure control and immune responses, we aimed to investigate whether there was a relationship between 25OHD status and the prevalence of metabolic syndrome in an Iranian population. MATERIAL/ METHODS: The study was carried out on a sample of 846 subjects [357(42.19%) males and 489(57.80%) females], derived from MASHAD STUDY. Serum 25OHD levels were measured using a competitive electroluminescence protein binding assay. Anthropometric indices were measured using standard protocols. RESULTS: Serum 25OHD was 12.7 (6.8-18.4) ng/ml in the metabolic syndrome (MetS) group and 14.1 (8.8-19.0) ng/ml in the group without metabolic syndrome (P=0.43). The frequency of vitamin D deficiency was 80.7% and 79.0% in subjects with or without metabolic syndrome in Iranian population. CONCLUSIONS: We found no significant difference in serum 25OHD concentrations between individuals with or without MetS and no significant linear relationship between serum 25OHD and several CVD risk factors.